Foundation Medicine, Inc. (NASDAQ:FMI) Director Krishna Yeshwant sold 18,072 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $36.85, for a total transaction of $665,953.20. Following the sale, the director now owns 5,786 shares in the company, valued at $213,214.10. The sale was disclosed in a filing with the SEC, which is available at this link.
Krishna Yeshwant also recently made the following trade(s):
- On Tuesday, August 8th, Krishna Yeshwant sold 4,800 shares of Foundation Medicine stock. The shares were sold at an average price of $40.01, for a total transaction of $192,048.00.
Shares of Foundation Medicine, Inc. (NASDAQ:FMI) traded up 1.25% during trading on Friday, reaching $36.55. 243,622 shares of the company’s stock were exchanged. The stock’s market cap is $1.32 billion. The company has a 50 day moving average of $38.04 and a 200 day moving average of $34.05. Foundation Medicine, Inc. has a 12-month low of $17.10 and a 12-month high of $43.15.
Foundation Medicine (NASDAQ:FMI) last released its quarterly earnings results on Tuesday, August 1st. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.08) by $0.16. The company had revenue of $35 million during the quarter, compared to analysts’ expectations of $34.94 million. Foundation Medicine had a negative net margin of 131.79% and a negative return on equity of 109.63%. Foundation Medicine’s revenue was up 23.9% on a year-over-year basis. During the same period last year, the firm posted ($0.84) earnings per share. Equities research analysts anticipate that Foundation Medicine, Inc. will post ($4.64) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by BNB Daily and is owned by of BNB Daily. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/krishna-yeshwant-sells-18072-shares-of-foundation-medicine-inc-fmi-stock-updated.html.
Several equities analysts recently commented on the stock. BidaskClub upgraded shares of Foundation Medicine from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Zacks Investment Research upgraded shares of Foundation Medicine from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. ValuEngine upgraded shares of Foundation Medicine from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, BTIG Research upgraded shares of Foundation Medicine from a “neutral” rating to a “buy” rating and set a $39.00 price target on the stock in a report on Monday, May 15th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. Foundation Medicine presently has an average rating of “Hold” and a consensus target price of $29.50.
Several large investors have recently added to or reduced their stakes in the stock. Fiduciary Trust Co. bought a new stake in Foundation Medicine during the second quarter worth about $119,000. Legal & General Group Plc increased its stake in Foundation Medicine by 8.6% in the second quarter. Legal & General Group Plc now owns 3,442 shares of the company’s stock worth $138,000 after buying an additional 274 shares during the period. Creative Planning increased its stake in Foundation Medicine by 10.0% in the first quarter. Creative Planning now owns 4,400 shares of the company’s stock worth $142,000 after buying an additional 400 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in Foundation Medicine by 5.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,898 shares of the company’s stock worth $193,000 after buying an additional 583 shares during the period. Finally, Bank of America Corp DE increased its stake in Foundation Medicine by 65.8% in the first quarter. Bank of America Corp DE now owns 6,180 shares of the company’s stock worth $200,000 after buying an additional 2,452 shares during the period. 30.89% of the stock is currently owned by institutional investors and hedge funds.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.